Enhancement in antimicrobial efficacy and biodegradation of natural rubber latex through graphene oxide/nickel oxide nanoparticles.

This work aims to fabricate antibacterial natural rubber latex composites by introducing different ratios of graphene oxide (GO) and nickel oxide (NiO) nanoparticles. The nanocomposites were prepared using latex mixing and a two-roll mill process, followed by molding with a heating hydraulic press. Detailed analyses were conducted to evaluate the rheological, chemical, physical, thermal, mechanical, and electrical performance of the composites. Fourier transform infrared spectroscopy (FTIR) was employed to analyze the interaction among different components, while the surface morphology was examined through the field emission scanning electron microscopy (FESEM) technique. The composites with a loading ratio of 1:2 of GO to NiO (optimized concentration) exhibited the highest tensile strength (24.9 MPa) and tear strength (47.4 N/ mm) among all the tested samples. In addition, the composites demonstrated notable antimicrobial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans. The thermal stability of the composites was observed up to 315 °C, and their electrical resistivity lies in the insulating range across a temperature span of 25 °C to 50 °C. The research uncovers critical insights into advancing composite materials suitable for diverse applications, featuring inherent antibacterial attributes, robust mechanical properties, resilience to solvent, UV shielding properties, and controlled electrical resistivity capabilities.

Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers.

Reinvigorating the killing function of tumor-infiltrating immune cells through the targeting of regulatory molecules expressed on lymphocytes has markedly improved the prognosis of cancer patients, particularly in melanoma. While initially thought to solely strengthen adaptive T lymphocyte anti-tumor activity, recent investigations suggest that other immune cell subsets, particularly tissue-resident innate lymphoid cells (ILCs), may benefit from immunotherapy treatment. Here, we describe the recent findings showing immune checkpoint expression on tissue-resident and tumor-infiltrating ILCs and how their effector function is modulated by checkpoint blockade-based therapies in cancer. We discuss the therapeutic potential of ILCs beyond the classical PD-1 and CTLA-4 regulatory molecules, exploring other possibilities to manipulate ILC effector function to further impede tumor growth and quench disease progression.